Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Lipid-modified aminoglycoside derivatives for in vivo siRNA delivery.

Zhang Y, Pelet JM, Heller DA, Dong Y, Chen D, Gu Z, Joseph BJ, Wallas J, Anderson DG.

Adv Mater. 2013 Sep 6;25(33):4641-5. doi: 10.1002/adma.201301917. Epub 2013 Jun 27.

2.

Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference.

Desigaux L, Sainlos M, Lambert O, Chevre R, Letrou-Bonneval E, Vigneron JP, Lehn P, Lehn JM, Pitard B.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16534-9. Epub 2007 Oct 8.

3.

Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.

Alabi CA, Love KT, Sahay G, Yin H, Luly KM, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):12881-6. doi: 10.1073/pnas.1306529110. Epub 2013 Jul 23.

4.

Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles.

Wang M, Alberti K, Varone A, Pouli D, Georgakoudi I, Xu Q.

Adv Healthc Mater. 2014 Sep;3(9):1398-403. doi: 10.1002/adhm.201400039. Epub 2014 Feb 20.

PMID:
24574196
5.

Cell penetrating peptide-mediated systemic siRNA delivery to the liver.

Hayashi Y, Yamauchi J, Khalil IA, Kajimoto K, Akita H, Harashima H.

Int J Pharm. 2011 Oct 31;419(1-2):308-13. doi: 10.1016/j.ijpharm.2011.07.038. Epub 2011 Jul 30.

PMID:
21827843
6.

pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.

Kolli S, Wong SP, Harbottle R, Johnston B, Thanou M, Miller AD.

Bioconjug Chem. 2013 Mar 20;24(3):314-32. doi: 10.1021/bc3004099. Epub 2013 Mar 7.

PMID:
23305315
7.

Lipid-based nanoparticles in the systemic delivery of siRNA.

Lin Q, Chen J, Zhang Z, Zheng G.

Nanomedicine (Lond). 2014 Jan;9(1):105-20. doi: 10.2217/nnm.13.192. Review.

PMID:
24354813
8.

Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery.

Whitehead KA, Sahay G, Li GZ, Love KT, Alabi CA, Ma M, Zurenko C, Querbes W, Langer RS, Anderson DG.

Mol Ther. 2011 Sep;19(9):1688-94. doi: 10.1038/mt.2011.141. Epub 2011 Jul 12.

9.

Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.

Tam YY, Chen S, Zaifman J, Tam YK, Lin PJ, Ansell S, Roberge M, Ciufolini MA, Cullis PR.

Nanomedicine. 2013 Jul;9(5):665-74. doi: 10.1016/j.nano.2012.11.006. Epub 2012 Dec 6.

PMID:
23219877
10.

In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery.

Whitehead KA, Matthews J, Chang PH, Niroui F, Dorkin JR, Severgnini M, Anderson DG.

ACS Nano. 2012 Aug 28;6(8):6922-9. doi: 10.1021/nn301922x. Epub 2012 Jul 6.

11.

Recent developments in nanoparticle-based siRNA delivery for cancer therapy.

Lee JM, Yoon TJ, Cho YS.

Biomed Res Int. 2013;2013:782041. doi: 10.1155/2013/782041. Epub 2013 Jun 17. Review.

12.

Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.

Suzuki Y, Ishihara H.

Int J Pharm. 2016 Aug 20;510(1):350-8. doi: 10.1016/j.ijpharm.2016.06.124. Epub 2016 Jun 29.

PMID:
27374199
13.

Lipid-like materials for low-dose, in vivo gene silencing.

Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9. doi: 10.1073/pnas.0910603106. Epub 2010 Jan 11. Erratum in: Proc Natl Acad Sci U S A. 2010 May 25;107(21):9915.

14.

siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo.

Suzuki Y, Hyodo K, Tanaka Y, Ishihara H.

J Control Release. 2015 Dec 28;220(Pt A):44-50. doi: 10.1016/j.jconrel.2015.10.024. Epub 2015 Oct 19.

PMID:
26478014
15.

Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.

Mahon KP, Love KT, Whitehead KA, Qin J, Akinc A, Leshchiner E, Leshchiner I, Langer R, Anderson DG.

Bioconjug Chem. 2010 Aug 18;21(8):1448-54. doi: 10.1021/bc100041r.

16.

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape.

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stöter M, Epstein-Barash H, Zhang L, Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M, Zerial M.

Nat Biotechnol. 2013 Jul;31(7):638-46. doi: 10.1038/nbt.2612. Epub 2013 Jun 23.

PMID:
23792630
17.

SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment.

Liu H, Li Y, Mozhi A, Zhang L, Liu Y, Xu X, Xing J, Liang X, Ma G, Yang J, Zhang X.

Biomaterials. 2014 Aug;35(24):6519-33. doi: 10.1016/j.biomaterials.2014.04.033. Epub 2014 May 5.

PMID:
24797882
18.

Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.

Zhong J, Huang HL, Li J, Qian FC, Li LQ, Niu PP, Dai LC.

Hepatobiliary Pancreat Dis Int. 2015 Feb;14(1):82-9.

PMID:
25655295
19.

Polyene-based cationic lipids as visually traceable siRNA transfer reagents.

Jubeli E, Raju L, Khalique NA, Bilchuk N, Zegel C, Chen A, Lou HH, Øpstad CL, Zeeshan M, Sliwka HR, Partali V, Leopold PL, Pungente MD.

Eur J Pharm Biopharm. 2015 Jan;89:280-9. doi: 10.1016/j.ejpb.2014.12.011. Epub 2014 Dec 20.

PMID:
25536113
20.

Alkane-modified short polyethyleneimine for siRNA delivery.

Schroeder A, Dahlman JE, Sahay G, Love KT, Jiang S, Eltoukhy AA, Levins CG, Wang Y, Anderson DG.

J Control Release. 2012 Jun 10;160(2):172-6. doi: 10.1016/j.jconrel.2011.11.030. Epub 2011 Dec 2.

Supplemental Content

Support Center